Drug Profile
ALN HBV
Alternative Names: ALN-HBVLatest Information Update: 15 Nov 2017
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 03 Nov 2017 Alnylam Pharmaceuticals terminates a phase I/II trial in Hepatitis B in United Kingdom (SC) (NCT02826018)
- 19 Oct 2017 Discontinued - Phase-I/II for Hepatitis B in United Kingdom (SC)
- 19 Oct 2017 Discontinued - Preclinical for Hepatitis B in USA (SC)